Dihexa
Grade CAnimal studies show dramatic effects on spatial memory and synaptic density. No controlled human data exists; safety profile in humans is unknown.
Mechanism of Action
Hexapeptide derivative of angiotensin IV. Reported to potentiate hepatocyte growth factor (HGF)/c-Met signaling, promoting synaptogenesis and dendritic spine formation in preclinical models.
Typical Protocol
Dose
8–45 mg (anecdotal)
Frequency
Daily
Duration
Short cycles only
Timing
Morning
Route
Oral or transdermal (research)
Half-life
Estimated short (oral bioavailability reported)
Educational reference only — not medical advice.
Reported Benefits
- Synaptogenesis in rodent hippocampus
- Reversal of scopolamine-induced cognitive deficits (rodents)
- Reported subjective cognitive enhancement (anecdotal)
Side Effects
- Unknown long-term human safety
- Theoretical proliferative risk via HGF/c-Met
Contraindications
- Active or prior malignancy
- Pregnancy
- Family cancer history
Known Interactions
Tyrosine kinase modulatorsMechanistic overlap with c-Met signaling.
References
Comparison vs Alternatives
All Peptides →| Attribute | DihexaThis page | Pinealon | Semaglutide |
|---|---|---|---|
| Evidence | Grade C | Grade C | Grade A |
| Category | Cognitive | Cognitive | Metabolic |
| Best for | Cognitive plasticity (preclinical) | Cognitive resilience (research) | GLP-1 receptor agonist |
| Typical dose | 8–45 mg (anecdotal) | 1–10 mg | 0.25 → 2.4 mg |
| Frequency | Daily | Daily | Weekly |
| Route | Oral or transdermal (research) | Intranasal or subcutaneous | Subcutaneous weekly (oral form available) |
| Legal status | Research chemical. Not approved for human use. Significant unknown oncologic risk. | Research chemical; not approved for human therapeutic use. | FDA-approved (Ozempic, Wegovy). Prescription required. |
| Action | Current page | View → | View → |